Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 309491, 10 pages
Clinical Study

Role of Genetic Polymorphisms of Deoxycytidine Kinase and Cytidine Deaminase to Predict Risk of Death in Children with Acute Myeloid Leukemia

1Hospital Infantil de México Federico Gómez, Department of Hematology and Oncology, Calle Doctor Márquez 162, Colonia Doctores, Delegación Cuauhtémoc, 06720 Mexico City, DF, Mexico
2Hospital Infantil de México Federico Gómez, Research Division, Calle Doctor Márquez 162, Colonia Doctores, Delegación Cuauhtémoc, 06720 Mexico City, DF, Mexico

Received 15 May 2014; Revised 2 September 2014; Accepted 10 September 2014

Academic Editor: Juan Manuel Mejía-Aranguré

Copyright © 2015 Aurora Medina-Sanson et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Cytarabine is one of the most effective antineoplastic agents among those used for the treatment of acute myeloid leukemia. However, some patients develop resistance and/or severe side effects to the drug, which may interfere with the efficacy of the treatment. The polymorphisms of some Ara-C metabolizing enzymes seem to affect outcome and toxicity in AML patients receiving cytarabine. We conducted this study in a cohort of Mexican pediatric patients with AML to investigate whether the polymorphisms of the deoxycytidine kinase and cytidine deaminase enzymes are implicated in clinical response and toxicity. Bone marrow and/or peripheral blood samples obtained at diagnosis from 27 previously untreated pediatric patients with de novo AML were processed for genotyping and in vitro chemosensitivity assay, and we analyzed the impact of genotypes and in vitro sensitivity on disease outcome and toxicity. In the multivariate Cox regression analysis, we found that age at diagnosis, wild-type genotype of the CDA A79C polymorphism, and wild-type genotype of the dCK C360G polymorphism were the most significant prognostic factors for predicting the risk of death.